Gan & Lee Pharmaceuticals. (603087.SS)
CNY 45.28
(0.67%)
CNY 45.28
(0.67%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 531.95 Million CNY | 308.86% |
| 2022 | -377.98 Million CNY | -109.95% |
| 2021 | 1.88 Billion CNY | 20.21% |
| 2020 | 1.58 Billion CNY | 9.07% |
| 2019 | 1.47 Billion CNY | 19.95% |
| 2018 | 1.21 Billion CNY | -5.89% |
| 2017 | 1.29 Billion CNY | 47.11% |
| 2016 | 894.03 Million CNY | 72.55% |
| 2015 | 519.26 Million CNY | 51.93% |
| 2014 | 340.22 Million CNY | 47.18% |
| 2013 | 231.47 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 156.37 Million CNY | 397.3% |
| 2024 Q1 | -81.47 Million CNY | 83.44% |
| 2024 Q3 | -62.16 Million CNY | -23.15% |
| 2023 Q3 | 72.79 Million CNY | -53.62% |
| 2023 Q1 | -8.09 Million CNY | 94.59% |
| 2023 Q2 | 156.96 Million CNY | 2039.31% |
| 2023 Q4 | 31.77 Million CNY | -56.35% |
| 2023 FY | - CNY | 308.86% |
| 2022 Q1 | 236.17 Million CNY | -71.97% |
| 2022 FY | - CNY | -109.95% |
| 2022 Q2 | -364.35 Million CNY | -254.27% |
| 2022 Q4 | -149.73 Million CNY | -27.62% |
| 2022 Q3 | -117.32 Million CNY | 67.8% |
| 2021 FY | - CNY | 20.21% |
| 2021 Q4 | 842.43 Million CNY | 89.05% |
| 2021 Q3 | 445.6 Million CNY | 7.92% |
| 2021 Q2 | 412.89 Million CNY | 460.4% |
| 2021 Q1 | 73.67 Million CNY | -87.07% |
| 2020 Q1 | 160.45 Million CNY | -72.48% |
| 2020 FY | - CNY | 9.07% |
| 2020 Q4 | 569.76 Million CNY | 2.95% |
| 2020 Q3 | 553.46 Million CNY | 112.65% |
| 2020 Q2 | 260.26 Million CNY | 62.21% |
| 2019 Q1 | 103.6 Million CNY | 0.0% |
| 2019 FY | - CNY | 19.95% |
| 2019 Q4 | 583.02 Million CNY | 24.6% |
| 2019 Q3 | 467.91 Million CNY | 82.92% |
| 2019 Q2 | 255.8 Million CNY | 146.91% |
| 2018 FY | - CNY | -5.89% |
| 2017 Q2 | 217.22 Million CNY | 0.0% |
| 2017 FY | - CNY | 47.11% |
| 2017 Q1 | 217.22 Million CNY | 0.0% |
| 2016 FY | - CNY | 72.55% |
| 2015 FY | - CNY | 51.93% |
| 2014 FY | - CNY | 47.18% |
| 2013 FY | - CNY | 0.0% |